Aurobindo Pharma secures USFDA approval for anti-infections drug
The approval from USFDA allows the Indian pharma company to manufacture and market Nafcillin injections.
Hyderabad, December 27, 2012: Aurobindo Pharma Ltd has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Nafcillin injections. It is worth noting here that Nafcillin for injection is a sterile semisynthetic penicillin (SSP) indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug.
The injection may also be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of susceptibility test results. The company also said in a release that the products are ready for immediate launch.